Peer-influenced content. Sources you trust. No registration required. This is HCN.
Eyewire+
Bayer agreed to acquire Perfuse Therapeutics in a deal valued at up to $2.45 billion, gaining full rights to a phase 2 endothelin receptor antagonist for glaucoma and diabetic retinopathy.
Ophthalmology May 18th 2026
Glaucoma Physician
“Despite more than 100 years of lowering intraocular pressure… too many patients still go blind.” — Eugene de Juan Jr, MD, UCSF
Neurology March 9th 2026
ALS News Today
“A 65% reduction in the risk of death and a statistically significant extension in median survival of over 14 months represent a clinically meaningful benefit of notable magnitude in ALS.” — Alon Ben-Noon, CEO, Neurosense Therapeutics
Neurology March 5th 2026
News Medical
“Creatine influences the exercise-dependent secretion of neurotransmitters and cytokines like serotonin and dopamine, which improve neural function and promote neuroplasticity.”
Family Medicine/General Practice August 5th 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS